The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Eleven Biotherapeutics, Inc. | COM | 286221106 | 43,187 | 4,841,591 | SH | DFND | 4,841,591 | 0 | 0 | ||
Foundation Medicine, Inc. | COM | 350465100 | 237,049 | 4,927,234 | SH | DFND | 4,927,234 | 0 | 0 | ||
Sage Therapeutics, Inc. | COM | 78667J108 | 490,901 | 9,773,073 | SH | DFND | 9,773,073 | 0 | 0 | ||
Zafgen Inc. | COM | 98885E103 | 166,443 | 4,202,045 | SH | DFND | 4,202,045 | 0 | 0 |